US Patent Issued to Providence Health & Services-Oregon, AgonOx on July 15 for "Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer" (Oregon, Washington Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,968, issued on July 15, was assigned to Providence Health & Services-Oregon (Portland, Ore.) and AgonOx Inc. (Portland, Ore.).

"Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer" was invented by Andrew D. Weinberg (Portland, Ore.), Ryan Montler (Camas, Wash.), Thomas Duhen (Portland, Ore.) and Rebekka Duhen (Portland, Ore.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid e...